The pharmaceutical sector spends $50 billion annually on clinical trials, yet 90% of candidate drugs fail to receive regulatory approval. Ingenix’s AI-powered clinical trial simulations could significantly reduce drug development timelines while maintaining quality standards and improving patient outcomes.
Today, the company secured a €9 million seed funding round led by Inovo.vc, a venture capital fund focusing on Central and Eastern European founders building global startups. OTB Ventures, the pan-European deep tech venture capital fund manager, and the International Finance Corporation (“IFC”) also participated in the round.
Bringing clinical trials to the next level
Piotr Surma and Adam Dancewicz co-founded Ingenix, leveraging their proven track record in AI startup development. They previously founded Applica, an AI startup specialising in proprietary multimodal LLMs, which Snowflake acquired in 2022.
Piotr Surma, co-founder and CEO at Ingenix, said: “The intricacies of human biology make developing AI technology in the pharmaceutical industry incredibly complex — but it’s possible. What our team is developing could revolutionise not just clinical trials but the entire sector by making drug development predictable.”
“The pharmaceutical industry has long awaited its ‘GPT moment.’ As we’ve seen repeatedly, tomorrow’s AI leaders can emerge anywhere, driven by intellect, creativity, and real-world focus. With our new investors’ support, we’re excited to fulfill Ingenix’s potential.”
Behind Ingenix: Technology for Simulating Clinical Trials Using AI Modelling
The company is developing proprietary technology that uses AI modeling to simulate and predict clinical trial outcomes. Ingenix acts as a groundbreaking multimodal and multiscale generative AI co-pilot for clinical development, enabling precise simulation of clinical drug trials.
Krzysztof Przybylak, Principal at Inovo.vc, noted: “Ingenix is tackling a research challenge that is both ambitious and complex. At this investment stage, the team is what truly matters. Few teams worldwide can address this problem, but after nearly a year of collaboration with Piotr and his team, we knew Ingenix was exceptional — and that we should lead this round.”
Ingenix operates across multiple scales, from molecular through cellular, tissue, and organism levels to populations, providing detailed predictions of clinical endpoints and potential adverse events across various drugs.
Wojtek Walniczek, Partner at OTB Ventures, commented: “At OTB Ventures, we back groundbreaking technologies that can revolutionise industries. Ingenix’s multi-modal and multiscale approach to AI-driven clinical trial simulation promises to enhance drug development’s efficiency and accuracy significantly. The impressive track record of co-founders Piotr and Adam reinforces our confidence in their ability to execute this ambitious vision. We’re eager to support Ingenix as they transform clinical trials and accelerate the delivery of new therapies to patients.”
Ary Naïm, World Bank Group Country Manager for Poland, said: “We’re delighted to support AI innovation from Poland, with strong potential for emerging market applications, particularly in improving cost and access. Our investment in Ingenix aligns with IFC’s digital health strategy and advances generative AI for clinical research, ensuring emerging markets benefit from these innovations.”
